BridgeBio Pharma (FRA:2CL) Current Deferred Revenue: €5.3 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:2CL BridgeBio Pharma Inc FRA:2CL
73 GF Score
Price €70.61
GF Value €129.90
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is BridgeBio Pharma Current Deferred Revenue?

BridgeBio Pharma FRA:2CL -1.44% 73 Current Deferred Revenue is €5.3 Mil as of Mar. 2026. GuruFocus rates FRA:2CL with a GF Score™ of 73/100 and a GF Value™ of €129.90 (Possible Value Trap). The stock has 8 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

BridgeBio Pharma's current deferred revenue for the quarter that ended in Mar. 2026 was €5.3 Mil.

BridgeBio Pharma Current Deferred Revenue Related Terms

BridgeBio Pharma Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for BridgeBio Pharma's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BridgeBio Pharma Current Deferred Revenue Chart

BridgeBio Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only 0.00 7.70 5.59 13.95 6.14

BridgeBio Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.75 9.14 7.74 6.14 5.29
FRA:2CL
73GF Score
BridgeBio Pharma Inc FRA:2CL
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of €5.3 Mil mean?
BridgeBio Pharma (FRA:2CL) has a Current Deferred Revenue of €5.3 Mil as of Mar. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on BridgeBio Pharma and its competitors.
Is BridgeBio Pharma's Current Deferred Revenue too high?
BridgeBio Pharma's current Current Deferred Revenue is €5.3 Mil. Overall, BridgeBio Pharma has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BridgeBio Pharma's Current Deferred Revenue compare to EXEL and IONS?
BridgeBio Pharma's Current Deferred Revenue of €5.3 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Biotechnology company?
A good Current Deferred Revenue depends on the Biotechnology industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on BridgeBio Pharma and its competitors. BridgeBio Pharma's current Current Deferred Revenue is €5.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BridgeBio Pharma stock overvalued right now?
Based on GuruFocus' analysis, BridgeBio Pharma (FRA:2CL) is currently considered Possible Value Trap. The stock's GF Value™ is €129.90, compared to a current price of €70.61 — trading 45.6% below its estimated fair value. The current Current Deferred Revenue is €5.3 Mil. BridgeBio Pharma's overall GF Score™ is 73/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For BridgeBio Pharma (FRA:2CL), the current Current Deferred Revenue is €5.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BridgeBio Pharma (FRA:2CL) Overvalued in 2026?

Based on GuruFocus' analysis, BridgeBio Pharma stock appears to be undervalued. The current stock price of €70.61 is trading 45.6% below its estimated GF Value™ of €129.90. GuruFocus considers BridgeBio Pharma to be Possible Value Trap.

Key valuation signals for FRA:2CL:

  • Current Deferred Revenue: €5.3 Mil
  • GF Value™: €129.90 vs. price of €70.61 (45.6% below fair value)
  • GF Score™: 73/100 with 8 warning signs

No single metric tells the full story. See the FRA:2CL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BridgeBio Pharma Business Description

Other Exchanges BBIO:USA1BBIO:Italy
Address 3160 Porter Drive, Suite 250, Palo Alto, CA, USA, 94304
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
73GF Score

Get the complete analysis for FRA:2CL

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€70.61
Price
€129.90
GF Value